Skip to main content
. 2024 Nov 11;15:1487940. doi: 10.3389/fphar.2024.1487940

SCHEME 1.

SCHEME 1

Schematic illustration of the mechanism of PD-1/SIRPα nanovesicles disrupting PD-L1/PD-1 and CD47/SIRPα axes for enhanced cancer immunotherapy.